Fresenius Medical profit drops less than feared, labour shortages ease
Adds shares, analyst comment
By Ludwig Burger
FRANKFURT, May 9 (Reuters) -Fresenius Medical Care FMEG.DE said on Tuesday labour shortages were slowly easing as the German dialysis specialist reported a drop in first-quarter adjusted operating income that was not as steep as some analysts had expected.
Adjusted operating income dropped to 354 million euros ($390 million), compared with the median analysts' estimate of 335 million posted on the company's website.
"The first quarter confirmed the trends towards improving treatment volumes and towards a stabilizing labor environment in the U.S," said CEO Helen Giza.
It confirmed its full-year outlook, saying adjusted operating income would likely remain flat or decline by up to a "high-single digit" percentage in 2023, which it has described as a transition year towards earnings growth recovery in 2024.
The dialysis group's parent, German healthcare group Fresenius SE FREG.DE has said this year it would cede control over the struggling dialysis firm, but keep its stake for now as part of a turnaround plan.
Fresenius said on Tuesday it was on track with those plans.
The move has been viewed by some investors as a prelude to an eventual sale of its stake in the dialysis group.
Fresenius Medical, which was hit hard by a high rate of COVID-19 deaths among its patients, said this burden was easing, though excess mortality continued to weigh on growth.
Its parent Fresenius said on Tuesday first-quarter operating earnings slipped a currency-adjusted 10%, also a better-than-expected result.
Shares in Fresenius Medical gained 1.4% at the open, while parent Fresenius' stock rose 3% to a two-month high.
"This is a good start to the year with improving fundamental signs in the business," Barclays analysts said.
Fresenius parent group CEO Michael Sen, who took over the helm last October, is cutting costs and has said the group would focus on generic hospital drugs unit Kabi and hospitals operator Helios, while Fresenius Medical and hospital project development firm Vamed would be treated as financial investments.
Reporting by Ludwig Burger; Editing by Sherry Jacob-Phillips
and Bernadette Baum
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
